Kyverna Therapeutics (KYTX) News Today $2.90 +0.07 (+2.30%) Closing price 07/3/2025 02:21 PM EasternExtended Trading$2.84 -0.05 (-1.73%) As of 07/3/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 2 at 9:00 PM | globenewswire.comKyverna Therapeutics Names Marc Grasso Chief Financial OfficerJune 30, 2025 | marketwatch.comKyverna Therapeutics Announces Appointment of New Chief Financial OfficerJune 30, 2025 | finance.yahoo.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from AnalystsJune 15, 2025 | marketbeat.com3 Promising Penny Stocks With Market Caps Over $100MJune 10, 2025 | finance.yahoo.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 20.6% in MayJune 4, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLCJune 1, 2025 | marketbeat.comKyverna Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comKyverna Therapeutics (NASDAQ:KYTX) Stock Rating Upgraded by HC WainwrightMay 28, 2025 | marketbeat.comHC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)May 27, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for KYTX EarningsMay 23, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Buy" by AnalystsMay 23, 2025 | marketbeat.comQ1 Earnings Forecast for KYTX Issued By HC WainwrightMay 22, 2025 | marketbeat.comSphera Funds Management LTD. Decreases Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 18, 2025 | marketbeat.comWith 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investorsMay 15, 2025 | finance.yahoo.comKYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 15, 2025 | globenewswire.comKyverna Therapeutics Reports Q1 2025 Progress and OutlookMay 14, 2025 | tipranks.comIntegral Health Asset Management LLC Acquires 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 14, 2025 | marketbeat.comKyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comKyverna Therapeutics (KYTX) Expected to Announce Earnings on TuesdayMay 8, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from AnalystsApril 28, 2025 | marketbeat.comGilead Sciences Inc. Acquires New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)April 20, 2025 | marketbeat.comJPMorgan Chase & Co. Trims Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)April 17, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Holdings Trimmed by Franklin Resources Inc.April 15, 2025 | marketbeat.comEquities Analysts Offer Predictions for KYTX Q1 EarningsApril 8, 2025 | marketbeat.comHC Wainwright Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00April 5, 2025 | marketbeat.comKyverna Therapeutics price target lowered to $4 from $6 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comKyverna Therapeutics price target lowered to $20 from $40 at Morgan StanleyApril 2, 2025 | markets.businessinsider.comKyverna Therapeutics (NASDAQ:KYTX) Given New $20.00 Price Target at Morgan StanleyApril 2, 2025 | marketbeat.comKyverna Therapeutics price target lowered to $12 from $13 at UBSMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics sees cash and securities sufficient into 2027March 29, 2025 | markets.businessinsider.comKyverna Therapeutics files $250M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics Advances CAR T-Cell Therapy TrialsMarch 28, 2025 | tipranks.comKyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results, Misses Expectations By $0.04 EPSMarch 28, 2025 | marketbeat.comKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | prnewswire.comKyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025March 21, 2025 | seekingalpha.comKyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on TuesdayMarch 18, 2025 | marketbeat.comGRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF KYVERNA THERAPEUTICS, INC. (KYTX)March 14, 2025 | markets.businessinsider.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Buy" from AnalystsFebruary 13, 2025 | marketbeat.comKYTX stock touches 52-week low at $2.78 amid sharp annual declineFebruary 12, 2025 | msn.comFY2025 Earnings Estimate for KYTX Issued By Leerink PartnrsFebruary 10, 2025 | marketbeat.comInvestors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTXFebruary 7, 2025 | globenewswire.comKYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities LawsuitFebruary 7, 2025 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsFebruary 7, 2025 | prnewswire.comAnalysts Issue Forecasts for KYTX FY2029 EarningsFebruary 7, 2025 | marketbeat.comKyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTXFebruary 7, 2025 | prnewswire.comInvestors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTXFebruary 6, 2025 | globenewswire.comKYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action – KYTXFebruary 6, 2025 | globenewswire.comThe Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTXFebruary 6, 2025 | prnewswire.com Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address KYTX Media Mentions By Week KYTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYTX News Sentiment▼0.000.56▲Average Medical News Sentiment KYTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYTX Articles This Week▼37▲KYTX Articles Average Week Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DNTH News RLAY News IOVA News AMLX News DNA News ARVN News KROS News TNGX News MAZE News MGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
